Week in Review: Beijing's Jacobio Completes $174 Million Hong Kong IPO

Deals and Financings Jacobio of Beijing raised $174 million in a Hong Kong IPO to develop its portfolio of 12 novel drugs, developed in-house to be best-in-class therapies; China 's Transcenta Holding completed a $105 million funding round to support its near-commericalization stage antibody drug development operations; 3E Bioventures Capital, a Beijing healthcare investor, formed a JV with Regenacy Pharma of Massachusetts to develop a novel drug for peripheral neuropathies;   Company News   Hasten Biopharmaceutic will pay $322 million for rights to commercialize five Takeda Pharma prescription cardiovascular and metabolism products in China ; WuXi Biologics of Shanghai will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany ' Trials and Approvals   Legend Bio of Nanjing started a rolling submission of an application for US approval of its BCMA CAR-T therapy in multiple myeloma; CASI Pharma, a US-China biopharma, announced its partnered CD19 CAR-T product was granted Breakthrough Designation in China for leukemia; Ascentage Pharma reported its Bcl-xL inhibitor started a Phase I trial in the US to treat diabetic macular edema. Stock Symbols: (HK: 2269) (NSDQ: LEGN) (NSDQ: CASI) (HK: 6855) Share this with colleagues: // //